2026-03-05 08:30Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 73.44 billion, representing a year-on-year growth of 26.3%[4] - Gross profit for the same period was RMB 18.20 billion, with a year-on-year increase of 36.7%[4] - Operating profit reached RMB 3.80 billion, marking a significant growth of 158.5% compared to the previous year[4] - The non-IFRS profit for the year was RMB 6.53 billion, up 36.3% from the previous year, with a net profit margin of 8.9%[5] - In 2025, JD Health achieved revenue of RMB 73.4 billion, a year-on-year increase of 26.3%, with non-IFRS profit reaching RMB 6.5 billion, up 36.3%, and a net profit margin of 8.9%[11] - Revenue increased by 26.3% from RMB 58.2 billion in 2024 to RMB 73.4 billion in 2025, driven by a 24.8% increase in sales of pharmaceutical and health products[22] - Active user growth and increased online penetration of pharmaceutical and health product sales contributed to revenue growth, with service revenue rising by 34.1% to RMB 12.6 billion[22] - Gross profit rose to RMB 18.2 billion in 2025, with a gross margin of 24.8%, up from RMB 13.3 billion and a margin of 22.9% in 2024[24] - Net profit for 2025 was RMB 5.4 billion, an increase from RMB 4.2 billion in 2024[31] - For the fiscal year ending December 31, 2025, the company's annual profit was RMB 5,367,109 thousand, an increase from RMB 4,157,014 thousand in 2024, representing a growth of approximately 29%[33] - The non-IFRS profit for 2025 was RMB 6,533,004 thousand, compared to RMB 4,792,278 thousand in 2024, indicating a year-over-year increase of about 36%[33] - Basic earnings per share for 2025 increased to RMB 1.70 from RMB 1.32 in 2024, reflecting a 28.8% growth[49] - Net profit for 2025 was RMB 5,367,109 thousand, representing a 29.0% increase compared to RMB 4,157,014 thousand in 2024[50] User Engagement and Growth - The number of annual active users reached 217.7 million, reflecting the company's strong user engagement[5] - The number of annual active users reached 217.7 million by December 31, 2025[11] - The instant retail business saw a remarkable growth, with order volume increasing by 81.9% year-on-year[8] - JD Health launched over 100 new drugs throughout the year, significantly increasing its competitive advantage in the pharmaceutical supply chain[11] - The company expanded its home testing services to cover 27 cities, with a significant increase in order volume during the flu peak period[12] - JD Health established strategic partnerships with over a thousand expert doctors to enhance online diagnosis service quality[12] - The company signed strategic cooperation agreements with major pharmaceutical companies, including Novo Nordisk and Bayer, to explore innovations in digital marketing and patient services[14] - JD Health opened over 300 self-operated pharmacy stores by the end of 2025, enhancing its immediate retail capabilities[16] Expenses and Costs - Operating costs increased by 23.2% to RMB 55.2 billion in 2025, reflecting growth in self-operated sales of pharmaceutical and health products[23] - Fulfillment expenses grew by 26.3% to RMB 7.6 billion, maintaining a stable percentage of 10.4% of revenue[25] - Sales and marketing expenses increased by 26.0% to RMB 3.8 billion, also maintaining a stable percentage of 5.2% of revenue[26] - R&D expenses rose by 22.8% to RMB 1.6 billion, accounting for 2.2% of revenue, down from 2.3% in 2024[27] - General and administrative expenses decreased by 18.1% to RMB 1.2 billion, reducing its percentage of revenue from 2.4% to 1.6%[28] Cash Flow and Liquidity - The net cash generated from operating activities for 2025 was RMB 10,173,949 thousand, significantly higher than RMB 4,332,367 thousand in 2024, reflecting an increase of approximately 135%[35] - The total cash and cash equivalents at the end of 2025 amounted to RMB 31,784,669 thousand, up from RMB 22,628,872 thousand at the end of 2024, marking a growth of around 40%[35] - The company had no outstanding borrowings as of December 31, 2025, indicating a capital debt ratio of 0%[40] - The company reported a net cash outflow from investing activities of RMB 590,651 thousand in 2025, compared to a net inflow of RMB 3,146,444 thousand in 2024[35] - The company anticipates meeting its liquidity requirements through cash generated from operations and net proceeds from global offerings[35] Assets and Liabilities - The company reported a total asset increase to RMB 81,586,601 thousand in 2025, up from RMB 71,274,993 thousand in 2024[54] - Non-current assets rose significantly to RMB 25,237,863 thousand in 2025, compared to RMB 12,814,578 thousand in 2024[52] - Inventory increased to RMB 6,858,213 thousand in 2025, up from RMB 5,842,656 thousand in 2024, indicating a 17.4% rise[52] - Total liabilities increased to RMB 21,513,391 thousand in 2025 from RMB 16,034,155 thousand in 2024, reflecting a 34.3% rise[54] - Trade payables increased significantly to RMB 13,209,545 thousand in 2025 from RMB 10,423,314 thousand in 2024, reflecting a growth of 26.9%[61] Corporate Governance and Compliance - The company did not recommend any final dividend for the year ended December 31, 2025, consistent with 2024[62] - The company has complied with all applicable corporate governance codes, except for the absence of the chairman at the annual general meeting due to other commitments[63] - The audit committee has reviewed the audited consolidated financial statements for the year ended December 31, 2025, ensuring compliance with accounting policies and internal controls[66] - No securities were purchased, sold, or redeemed by the company or its subsidiaries during the reporting period[68] Future Plans and Investments - The company plans to deepen supply chain advantages and explore technological innovations and AI applications in 2026[8] - The net proceeds from the global offering, after deducting underwriting commissions and expenses, amount to approximately RMB 25.7 billion[70] - As of January 1, 2025, the unutilized net proceeds allocation includes RMB 9.01 billion for business expansion, specifically in retail pharmacy and online healthcare services[70] - Potential investments and acquisitions or strategic alliances are allocated RMB 2.911 billion, expected to be fully utilized within 12 to 36 months from March 6, 2025[70] - Working capital needs and general corporate purposes account for RMB 648 million, with RMB 579 million expected to be utilized within the same timeframe[70] - The total unutilized net proceeds as of December 31, 2025, is projected to be RMB 3.49 billion[70]